These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9512135)

  • 41. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
    Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
    Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of hepatitis G virus coinfection on severity of hepatitis C: relationship to risk factors and response to interferon treatment.
    Lin R; Dutta U; Kaba S; Kench J; Crewe E; Coverdale S; Byth K; Liddle C; Farrell GC
    J Gastroenterol Hepatol; 1998 Aug; 13(8):773-80. PubMed ID: 9736169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy.
    Soffredini R; Rumi MG; Parravicini ML; Ronchi G; Del Ninno E; Russo A; Colombo M
    Am J Gastroenterol; 2004 Sep; 99(9):1738-43. PubMed ID: 15330912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.
    Pawlotsky JM; Darthuy F; Rémiré J; Pellet C; Udin L; Stuyver L; Roudot-Thoraval F; Duvoux C; Douvin C; Mallat A
    J Med Virol; 1995 Nov; 47(3):285-91. PubMed ID: 8551282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5.
    Sarrazin C; Gärtner BC; Sizmann D; Babiel R; Mihm U; Hofmann WP; von Wagner M; Zeuzem S
    J Clin Microbiol; 2006 Mar; 44(3):729-37. PubMed ID: 16517847
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients.
    Dzekova P; Asani A; Selim G; Gelev S; Trajceska L; Amitov V; Selja N; Zabzun M; Mena S; Gaseva M; Sikole A
    Int J Artif Organs; 2009 Mar; 32(3):180-4. PubMed ID: 19440994
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitative measurement of serum HCV RNA in patients with chronic hepatitis C: comparison between Amplicor HCV monitor system and branched DNA signal amplification assay.
    Lu RH; Hwang SJ; Chan CY; Chang FY; Lee SD
    J Clin Lab Anal; 1998; 12(2):121-5. PubMed ID: 9524297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
    J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay].
    Matsuura K; Tanaka Y; Takagi K; Hiramatsu K; Kani S; Gotoh T; Wakimoto Y; Joh T; Mizokami M
    Rinsho Byori; 2007 Nov; 55(11):983-8. PubMed ID: 18154028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission.
    Papatheodoridis GV; Katsoulidou A; Touloumi G; Delladetsima JK; Hatzakis A; Tassopoulos NC
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):469-75. PubMed ID: 8804876
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection.
    Furusyo N; Hayashi J; Ariyama I; Sawayama Y; Etoh Y; Shigematsu M; Kashiwagi S
    Am J Gastroenterol; 2000 Feb; 95(2):490-6. PubMed ID: 10685756
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment.
    Sagnelli E; Coppola N; Scolastico C; Mogavero AR; Stanzione M; Filippini P; Felaco FM; Piccinino F
    J Med Virol; 2001 Dec; 65(4):681-7. PubMed ID: 11745931
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between the effect of interferon therapy and the change of hepatitis C virus non-structural 5B gene.
    Horiike N; Michitaka K; Masumoto T; Okura I; Akbar SM; Onji M
    J Gastroenterol Hepatol; 1999 Apr; 14(4):345-51. PubMed ID: 10207784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy.
    Colloredo G; Roffi L; Brunetto MR; Leandro G; Brugnetti B; Bissoli F; Scalori A; Mancia G; Civardi E; Idéo G; Bonino F; Bellati G
    J Viral Hepat; 1999 Sep; 6(5):373-80. PubMed ID: 10607253
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C.
    Martinot-Peignoux M; Khiri H; Leclere L; Maylin S; Marcellin P; Halfon P
    J Clin Virol; 2009 Nov; 46(3):216-21. PubMed ID: 19748822
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b.
    Tong MJ; Blatt LM; Tong LT; Sayadzadeh K; Conrad A
    J Viral Hepat; 1998 Sep; 5(5):323-31. PubMed ID: 9795916
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
    Roomer R; van Vuuren AJ; Schutten M; Heijens A; Janssen HL; de Knegt RJ
    Antivir Ther; 2011; 16(5):771-4. PubMed ID: 21817199
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay.
    Ferraro D; Giglio M; Bonura C; Di Marco V; Mondelli MU; Craxì A; Di Stefano R
    J Viral Hepat; 2008 Jan; 15(1):66-70. PubMed ID: 18088247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.